EA Pharma - About the company
EA Pharma is a funded company based in Tokyo (Japan), founded in 2016. It operates as a Japanese gastrointestinal specialty pharma. The company has 2500 active competitors, including 855 funded and 629 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics.
Company Details
EA Pharma is a Japanese gastrointestinal specialty pharma that was established in April 2016 through the integration of the gastrointestinal disease business of Eisai Group and the Ajinomoto Group’s amino acid-core business in the gastrointestinal field. The current pipeline of EA pharma covers the upper and lower digestive tract as well as the liver and pancreas. They have files NDA for AJG511 (budesonide) (Ulcerative colitis), E3810 (rabeprazole) (Maintenance therapy for proton pump inhibitor (PPI)-resistant reflux esophagitis), and AJG533 (elobixibat) (Chronic constipation).
- Website
- www.eapharma.co.jp
- Phone Number
- +81 **********
Key Metrics
Founded Year
2016
Location
Tokyo, Japan
Stage
Funding Raised
Investors
Ranked
1041st among 2500 active competitors
Investment & Acquisitions
Similar Companies
Sign up to download EA Pharma's company profile
EA Pharma's funding and investors
EA Pharma is a funded company. EA Pharma has 2 institutional investors.
View details of EA Pharma's funding rounds and investors
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
EA Pharma's Competitors and alternates
Top competitors of EA Pharma include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Here is the list of Top 10 competitors of EA Pharma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of genetically engineered cell therapies for multiple disorders | $821M | 75/100 | |
3rd | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 74/100 | |
4th | Juno Therapeutics 2013, Seattle (United States), Acquired | Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $317M | 74/100 | |
5th | Blueprint Medicines 2008, Cambridge (United States), Acquired | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | 72/100 | |
6th | _1548135965397.png?devicePixelRatio=2&height=30&width=30){kind=logo} Kronos Bio 2017, San Mateo (United States), Acquired | Developer of small molecule based therapeutics for cancer treatment | $271M | 72/100 | |
7th | MacroGenics 2000, Rockville (United States), Public | Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease | $126M | 71/100 | |
8th |  Harbour BioMed 2016, Shanghai (China), Public | Developer of antibody therapeutics in immunology and oncology disease | $313M | 71/100 | |
9th | _1545299782322.png?devicePixelRatio=2&height=30&width=30){kind=logo} Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | 70/100 | |
10th |  iTeos Therapeutics 2011, Cambridge (United States), Acquired | Developer of immunotherapy for treating cancer | $204M | 70/100 | |
1041st | Japanese gastrointestinal specialty pharma | - | 36/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on EA Pharma's competitors? Click here to see the top ones
EA Pharma's Investments and acquisitions
EA Pharma has acquired Stardea. EA Pharma has not made any investments as of now.Reports related to EA Pharma
Here is the latest report on EA Pharma's sector:
News related to EA Pharma
Filter this listMedia has covered EA Pharma for a total of 2 events in the last 1 year, 1 of them has been about company updates.
•
•
•
•
•
Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitorACN Newswire•Mar 28, 2022•Gilead Sciences, Eisai, EA Pharma
•
Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional ApprovalACN Newswire•Sep 26, 2021•AbbVie, Eisai, EA Pharma
•
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about EA Pharma
Explore our recently published companies
- Academy West Insurance Services - Fresno based, 1998 founded, Public company
- Optimo Capital - San Francisco based, 2010 founded, Unfunded company
- Ruvero - Lagos based, 2017 founded, Unfunded company
- Watermilltrading.com - 2009 founded, Unfunded company
- Firm Ridge - Orlando based, 2016 founded, Unfunded company
- Kingsport Press Credit Union - Rogersville based, 1930 founded, Unfunded company
